1542706-34-2

Upstream product

• 52488-36-5 4-bromo-1H-indole 
• 1542711-55-6 N-benzyl-2-chloro-7,8-di-hydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 944902-88-9 2,4-dichloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1478126-83-8 7, 8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diol 
• 1542711-49-8 methyl 4-amino-5,6-dihydro-2H-pyran-3-carboxylate 
• 127956-11-0 4-oxotetrahydro-2H-pyran-3-carboxylic acid methyl ester 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 34058-51-0 methyl 2-methyl-1H-indole-4-carboxylate 
• 6127-18-0 4-bromo-2-methyl-1H-indole 
• 1232861-11-8 4-bromo-2-methyl-1-(phenylsulfonyl)-1H-indole 
• 412048-77-2 1‐(benzenesulfonyl)‐4‐bromo‐1H‐indole 

Downstream Products

• 1542706-15-9 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-N,2-dimethyl-1H-indole-4-carboxamide 

Relevant academic research and scientific papers

Discovery of Irreversible p97 Inhibitors

Inhibitors of human p97 (also known as valosin-containing protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases. However, covalent and irreversible p97 inhibitors have not been well explored.

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.